Journal of The Academy of Clinical Microbiologists

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  26 (2024)
Volume  23 (2021)
Volume  22 (2020)
Volume  21 (2019)
Volume  20 (2018)
Volume  19 (2017)
Volume  18 (2016)
Volume  17 (2015)
Volume  16 (2014)
Volume  15 (2013)
Related articles

VOLUME 19 , ISSUE 2 ( July-December, 2017 ) > List of Articles

REVIEW ARTICLE

Colistin: Pharmacology, drug resistance and clinical applications

Parijat Das, Kasturi Sengupta, Gaurav Goel, Sanjay Bhattacharya

Keywords : Colistin, cost, drug resistance, generic brands, nephrotoxicity, neurotoxicity, pharmacodynamics, pharmacokinetics, pharmacology, Polymyxin, therapeutic drug monitoring

Citation Information : Das P, Sengupta K, Goel G, Bhattacharya S. Colistin: Pharmacology, drug resistance and clinical applications. 2017; 19 (2):77-85.

DOI: 10.4103/jacm.jacm_31_17

License: CC BY-NC 4.0

Published Online: 17-08-2024

Copyright Statement:  Copyright © 2017; Wolters Kluwer India Pvt. Ltd.


Abstract

Colistin is an important antibiotic against multidrug-resistant (MDR) Gram-negative bacteria (GNB), particularly Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Although it is an old antibiotic, Colistin has emerged as an important agent in the treatment of GNB infections, especially those caused by MDR pathogens in hospitalised patients. Limited therapeutic option against Carbapenem-resistant Gram-negative bacilli (E. coli, Klebsiella, Pseudomonas and Acinetobacter) is one of the major problems in clinical practice. The current review discusses the pharmacology, toxicity, drug resistance, importance of therapeutic drug level monitoring and cost of one of the most important antibiotics in the current practice.

PDF Share
  1. Koyama Y, Kurosawa A, Tsuchiya A, Takemuta K. A new antibiotic ‘Colistin’ produced by spore-forming soil bacteria. J Antibiot (Tokyo) 1950;3:457-8.
  2. Gurjar M. Colistin for lung infection: An update. J Intensive Care 2015;3:3.
  3. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized Colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005;41:754-7.
  4. Li J. Difficulty in assaying Colistin methanesulphonate. Clin Microbiol Infect 2005;11:773-4.
  5. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
  6. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
  7. Gobin P, Lemaître F, Marchand S, Couet W, Olivier JC. Assay of Colistin and Colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010;54:1941-8.
  8. Martin NI, Hu H, Moake MM, Churey JJ, Whittal R, Worobo RW, et al. Isolation, structural characterization, and properties of mattacin (polymyxin M), a cyclic peptide antibiotic produced by Paenibacillus kobensis M. J Biol Chem 2003;278:13124-32.
  9. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW, et al. A simple method for the assay of Colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001;761:167-75.
  10. Froman J, Gross L, Curatola S. Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol 1970;103:210-4.
  11. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of Colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25.
  12. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979;18:4425-30.
  13. Falagas ME, Makris GC, Dimopoulos G, Matthaiou DK. Heteroresistance: A concern of increasing clinical significance? Clin Microbiol Infect 2008;14:101-4.
  14. Hjort K, Nicoloff H, Andersson DI. Unstable tandem gene amplification generates heteroresistance (variation in resistance within a population) to Colistin in Salmonella enterica. Mol Microbiol 2016;102:274-89.
  15. Kim SH, Jia W, Parreira VR, Bishop RE, Gyles CL. Phosphoethanolamine substitution in the lipid A of Escherichia coli O157: H7 and its association with PmrC. Microbiology 2006;152:657-66.
  16. Jayol A, Nordmann P, Brink A, Poirel L. Heteroresistance to Colistin in Klebsiella pneumoniae associated with alterations in the PhoPQ regulatory system. Antimicrob Agents Chemother 2015;59:2780-4.
  17. Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, et al. In vivo emergence of Colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother 2013;57:5521-6.
  18. Clements A, Tull D, Jenney AW, Farn JL, Kim SH, Bishop RE, et al. Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J Biol Chem 2007;282:15569-77.
  19. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: Acquired and intrinsic resistance in bacteria. Front Microbiol 2014;5:643.
  20. Srinivasan VB, Rajamohan G. KpnEF, a new member of the Klebsiella pneumoniae cell envelope stress response regulon, is an SMR-type efflux pump involved in broad-spectrum antimicrobial resistance. Antimicrob Agents Chemother 2013;57:4449-62.
  21. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010;54:4971-7.
  22. Pelletier MR, Casella LG, Jones JW, Adams MD, Zurawski DV, Hazlett KR, et al. Unique structural modifications are present in the lipopolysaccharide from Colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2013;57:4831-40.
  23. Macfarlane EL, Kwasnicka A, Ochs MM, Hancock RE. PhoP-phoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Mol Microbiol 1999;34:305-16.
  24. Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK, et al. Worldwide emergence of Colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: An epidemiological and molecular study. Int J Antimicrob Agents 2014;44:500-7.
  25. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: An update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 2012;10:917-34.
  26. Arduino SM, Quiroga MP, Ramírez MS, Merkier AK, Errecalde L, Di Martino A, et al. Transposons and integrons in Colistin-resistant clones of Klebsiella pneumoniae and Acinetobacter baumannii with epidemic or sporadic behaviour. J Med Microbiol 2012;61:1417-20.
  27. Goel G, Hmar L, Sarkar De M, Bhattacharya S, Chandy M. Colistin-resistant Klebsiella pneumoniae: Report of a cluster of 24 cases from a new oncology center in Eastern India. Infect Control Hosp Epidemiol 2014;35:1076-7.
  28. Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, et al. Outbreak of Colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011;55:593-9.
  29. Strenger V, Gschliesser T, Grisold A, Zarfel G, Feierl G, Masoud L, et al. Orally administered Colistin leads to Colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteria in hospitalised newborns. Int J Antimicrob Agents 2011;37:67-9.
  30. Chen S, Hu F, Zhang X, Xu X, Liu Y, Zhu D, et al. Independent emergence of Colistin-resistant Enterobacteriaceae clinical isolates without Colistin treatment. J Clin Microbiol 2011;49:4022-3.
  31. Antimicrobial Resistance Empirical and Statistical Evidence- Base, A Report from the Department of Health Antimicrobial Resistance Strategy Analytical Working Group. Public Health. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553267/AMR_EBO_2016.pdf. [Last accessed on 2017 Dec 14].
  32. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58:2322-8.
  33. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2011;66:946-7.
  34. Hermes DM, Pormann Pitt C, Lutz L, Teixeira AB, Ribeiro VB, Netto B, et al. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa. J Med Microbiol 2013;62:1184-9.
  35. Linden PK, Paterson DL. Parenteral and inhaled Colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43 Suppl 2:S89-94.
  36. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous Colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78-83.
  37. Karabinis A, Paramythiotou E, Mylona-Petropoulou D, Kalogeromitros A, Katsarelis N, Kontopidou F, et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 2004;38:e7-9.
  38. Abat C, Desboves G, Olaitan AO, Chaudet H, Roattino N, Fournier PE, et al. Increasing burden of urinary tract infections due to intrinsic Colistin-resistant bacteria in hospitals in Marseille, France. Int J Antimicrob Agents 2015;45:144-50.
  39. Pallett A, Hand K. Complicated urinary tract infections: Practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother 2010;65 Suppl 3:iii25-33.
  40. Electronic Medicines Compendium (eMC), Available from: https://www.medicines.org.uk/emc/. [Last accessed on 2017 Dec 14].
  41. Schülin T. In vitro activity of the aerosolized agents Colistin and Tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in Southwestern Germany. J Antimicrob Chemother 2002;49:403-6.
  42. Karvanen M, Malmber C, Mohamed A, Lagerback P, Friberg LE, Cars O. Colistin is extensively lost during normal experimental conditions, abstracts D-690. Abstracts 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2011.
  43. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. PA, USA: CLSI; 2015.
  44. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of Colistin resistance among patients with Carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013;19:E23-30.
  45. Halaby T, Al Naiemi N, Kluytmans J, van der Palen J, Vandenbroucke-Grauls CM. Emergence of Colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an Intensive Care Unit. Antimicrob Agents Chemother 2013;57:3224-9.
  46. FAO/OIE/WHO. Non-Human Antimicrobial Usage and Antimicrobial Resistance. Geneva; 2003. Available from: http://apps.who.int/iris/bitstream/10665/68883/1/WHO_CDS_CPE_ZFK_2004.7.pdf. [Last accessed on 2017 Dec 14].
  47. Ma Z, Wang J, Gerber JP, Milne RW. Determination of Colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2008;862:205-12.
  48. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated Colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect Dis 2016;16:161-8.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.